Endocrine Abstracts

Background: Gestational diabetes mellitus (GDM) is associated with increased rates of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) infants. Currently, it is not possible to predict which women with GDM are at risk of delivering LGA or SGA infants. Fetuin-A, (α 2-Heremans Schmid glycoprotein; AHSG), a glycoprotein associated with insulin resistance is altered in GDM maternal serum. It is unclear if levels are related to altered fetal growth. This stud...

Pregnancies affected by GDM commonly result in large-for-gestational-age (LGA) infants, which have an increased risk of developing cardiometabolic complications. The mechanisms responsible are unclear but are associated with altered placental physiology. We have previously reported that miRNAs, including pancreatic specific miR-375, are altered in maternal serum extracellular vesicles (EVs) prior to the onset of LGA, and in term placenta. We assessed maternal pancreatic-derive...

Metformin is a first-line therapy for type-2 diabetes mellitus and gestational diabetes mellitus (GDM) which shows significant benefits for maternal health. However, offspring exposed to metformin in-utero have an increased risk of being born small for gestational age and developing cardiometabolic complications in adulthood. The mechanisms responsible are unknown. As fetal growth is dependent on optimal placental function, we assessed whether metformin exposure alter...